Jodi Saunus

Regulation of BRCA1 messenger RNA stability in human epithelial cell lines and during cell cycle progression.

Cellular and molecular mechanisms of resistance to oral Candida albicans infections.

Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding protein HuR.

Molecular aspects of breast cancer metastasis to the brain.

In vitro analysis of breast cancer cell line tumourspheres and primary human breast epithelia mammospheres demonstrates inter- and intrasphere heterogeneity.

Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines.

ID4 controls mammary stem cells and marks breast cancers with a stem cell-like phenotype.

Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.

Novel highly specific anti-periostin antibodies uncover the functional importance of the fascilin 1-1 domain and highlight preferential expression of periostin in aggressive breast cancer.

The calcium pump plasma membrane Ca(2+)-ATPase 2 (PMCA2) regulates breast cancer cell proliferation and sensitivity to doxorubicin.

Long-range regulators of the lncRNA HOTAIR enhance its prognostic potential in breast cancer.

SASH1 mediates sensitivity of breast cancer cells to chloropyramine and is associated with prognosis in breast cancer.

'Omics Approaches in Breast Cancer Research and Clinical Practice.

Breast Cancer Brain Metastases: Clonal Evolution in Clinical Context.

Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.

Mixed ductal-lobular carcinomas: evidence for progression from ductal to lobular morphology.

Expression of MAGE-A and NY-ESO-1 cancer/testis antigens is enriched in triple-negative invasive breast cancers.

Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient.

CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer.

Breast cancer metastasis to gynaecological organs: a clinico-pathological and molecular profiling study.

Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications.

Recent advances in breast cancer research impacting clinical diagnostic practice.

Calcium signalling and breast cancer.

Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer.

Innovative Therapeutic Strategies for Effective Treatment of Brain Metastases.

Correction: DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer.

Proteomic Analysis of the Breast Cancer Brain Metastasis Microenvironment.

LobSig is a multigene predictor of outcome in invasive lobular carcinoma.

Breast Cancer Heterogeneity in Primary and Metastatic Disease.

Non-coding RNAs underlie genetic predisposition to breast cancer.

Tradeoff between metabolic i-proteasome addiction and immune evasion in triple-negative breast cancer.

Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor-Positive Breast Cancer.

Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1.

Clinicopathologic significance of nuclear HER4 and phospho-YAP(S) in human breast cancers and matching brain metastases.

The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence.

Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases.

Altered Calcium Influx Pathways in Cancer-Associated Fibroblasts.

Landscape of Epidermal Growth Factor Receptor Heterodimers in Brain Metastases.

Emerging Biomarkers for Diagnosis, Prevention and Treatment of Brain Metastases-From Biology to Clinical Utility.

N-glycolylneuraminic acid serum biomarker levels are elevated in breast cancer patients at all stages of disease.

Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer.